Payment overview · 2025
General Payments
$131,900.03
218 reported records · 16 companies
Healthcare provider profile · identity verified
Prakash Krishnan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · NEW YORK, NY · NPI 1972547974
Verified facts
What the public records show
CMS Open Payments records show Prakash Krishnan, M.D. received $131,900.03 in general payments during 2025 across 218 reported records.
Abbott Laboratories accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $40,154.22 | 30.4% | 75 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $29,361.18 | 22.3% | 24 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$29,203.53 | 22.1% | 88 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $15,531.82 | 11.8% | 1 | 2025 |
| ASAHI INTECC CO., LTD. | Unresolved — no canonical attribution shown | $14,775.95 | 11.2% | 2 | 2025 |
| Cook Incorporated | Unresolved — no canonical attribution shown | $1,260.00 | 1.0% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $853.81 | 0.7% | 5 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $167.97 | 0.1% | 7 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $147.38 | 0.1% | 5 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $133.06 | 0.1% | 3 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $101.44 | 0.1% | 1 | 2025 |
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $80.72 | 0.1% | 2 | 2025 |
| Cagent Vascular INC | Unresolved — no canonical attribution shown | $58.98 | 0.0% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $32.98 | 0.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.15 | 0.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.84 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $53,648.55 | 38 |
| Consulting Fee | $27,700.00 | 11 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $24,358.75 | 5 |
| Acquisitions | $15,531.82 | 1 |
| Food and Beverage | $10,660.91 | 163 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $28,285.67 | 18 | 2025 |
Source payment records
|
|||||
| SUPERA Normalized: supera |
Device | Abbott Laboratories | $21,075.20 | 8 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $15,531.82 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN Endoprosthesis with Heparin Normalized: gore viabahn endoprosthesis with heparin |
Device | W. L. Gore & Associates, Inc. | $15,450.00 | 5 | 2025 |
Source payment records
|
|||||
| CROSSLEAD Normalized: crosslead |
Device | ASAHI INTECC CO., LTD. | $14,775.95 | 2 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $11,849.56 | 38 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROGLIDE Normalized: perclose proglide |
Device | Abbott Laboratories | $11,376.07 | 29 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $7,472.77 | 9 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $4,371.11 | 22 | 2025 |
Source payment records
|
|||||
| PROSTAR Normalized: prostar |
Device | Abbott Laboratories | $3,288.99 | 14 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $897.39 | 13 | 2025 |
Source payment records
|
|||||
| Product in Development Normalized: product in development |
Device | W. L. Gore & Associates, Inc. | $780.00 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $701.30 | 4 | 2025 |
Source payment records
|
|||||
| GORE VIATORR TIPS Endoprosthesis Normalized: gore viatorr tips endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $291.76 | 4 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $279.68 | 8 | 2025 |
Source payment records
|
|||||
| CHOCOLATE PTA BALLOON CATHETER Normalized: chocolate pta balloon catheter |
Device | Medtronic, Inc. | $159.57 | 2 | 2025 |
Source payment records
|
|||||
| LUTONIX Drug Coated Balloon Normalized: lutonix drug coated balloon |
Device | Bard Peripheral Vascular, Inc. | $152.51 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $147.38 | 5 | 2025 |
Source payment records
|
|||||
| SILVERHAWK Normalized: silverhawk |
Device | Medtronic, Inc. | $144.19 | 7 | 2025 |
Source payment records
|
|||||
| LIMFLOW SYSTEM Normalized: limflow system |
Device | Stryker Corporation | $102.11 | 2 | 2025 |
Source payment records
|
|||||
| ZILVER PTX Normalized: zilver ptx |
Device | Cook Medical LLC | $101.44 | 1 | 2025 |
Source payment records
|
|||||
| TURBOHAWK Normalized: turbohawk |
Device | Medtronic, Inc. | $95.12 | 5 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy Normalized: pounce thrombectomy |
Device | Surmodics, Inc. | $80.72 | 2 | 2025 |
Source payment records
|
|||||
| Pounce Venous Thrombectomy System Normalized: pounce venous thrombectomy system |
Device | Surmodics, Inc. | $80.72 | 2 | 2025 |
Source payment records
|
|||||
| IV Other Normalized: iv other |
Device | Philips North America LLC | $69.99 | 3 | 2025 |
Source payment records
|
|||||
| Serrantor Normalized: serrantor |
Device | Cagent Vascular INC | $58.98 | 1 | 2025 |
Source payment records
|
|||||
| Peripheral Vascular Undivided Normalized: peripheral vascular undivided |
Device | Philips North America LLC | $55.74 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy System Normalized: pounce thrombectomy system |
Device | Surmodics, Inc. | $49.78 | 1 | 2025 |
Source payment records
|
|||||
| Sublime 014 Rx PTA Balloon Dilatation Catheter Normalized: sublime 014 rx pta balloon dilatation catheter |
Device | Surmodics, Inc. | $49.78 | 1 | 2025 |
Source payment records
|
|||||
| Sublime Microcatheter, 018, 200cm, Straight Normalized: sublime microcatheter 018 200cm straight |
Device | Surmodics, Inc. | $49.78 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $33.76 | 1 | 2025 |
Source payment records
|
|||||
| Stellarex Normalized: stellarex |
Device | Philips North America LLC | $33.36 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $32.98 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $32.98 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $30.95 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $30.95 | 1 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $25.24 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT AV Normalized: in pact av |
Device | Medtronic, Inc. | $22.87 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| CONCERTOTM Normalized: concertotm |
Device | Medtronic, Inc. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| Labosys Normalized: labosys |
Device | Philips North America LLC | $8.88 | 1 | 2025 |
Source payment records
|
|||||
| VIATORR Endoprosthesis Normalized: viatorr endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $3.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 280 | 127 |
| Cephalexin | Cephalexin | 191 | 126 |
| Xarelto | Rivaroxaban | 95 | 31 |
| Atorvastatin Calcium | Atorvastatin Calcium | 44 | 22 |
| Gabapentin | Gabapentin | 43 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 43 | 18 |
| Pregabalin | Pregabalin | 39 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | 13 |
| Cilostazol | Cilostazol | 27 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 27 | 15 |
| Furosemide | Furosemide | 26 | 13 |
| Amlodipine Besylate | Amlodipine Besylate | 24 | 13 |
| Eliquis | Apixaban | 22 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 21 | suppressed |
| Carvedilol | Carvedilol | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Losartan Potassium | Losartan Potassium | 13 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $131,900.03 · 218 records | Abbott Laboratories | ABRE, CAMZYOS, CHOCOLATE PTA BALLOON CATHETER, CONCERTOTM, CROSSLEAD, CT THROMBECTOMY SYSTEM KIT, DIAMONDBACK PERIPHERAL, ESPRIT, FLOWTRIEVER CATHETER, S, Flexitouch Plus, GORE VIABAHN Endoprosthesis with Heparin, GORE VIABAHN VBX Balloon Expandable Endo, GORE VIATORR TIPS Endoprosthesis, General - Therapies, HAWKONE, IN.PACT ADMIRAL, IN.PACT AV, IV Other, LIMFLOW SYSTEM, LUTONIX Drug Coated Balloon, Labosys, MYNX CONTROL VENOUS, Nimbl, PERCLOSE PROGLIDE, PERCLOSE PROSTYLE, PROSTAR, Peripheral Vascular Undivided, Pounce Thrombectomy, Pounce Thrombectomy System, Pounce Venous Thrombectomy System, Product in Development, RotarexS 6 F x 135 cm, SILVERHAWK, SUPERA, SYMPLICITY G3, Serrantor, Stellarex, Sublime 014 Rx PTA Balloon Dilatation Catheter, Sublime Microcatheter, 018, 200cm, Straight, TURBOHAWK, VENASEAL, VIATORR Endoprosthesis, ZILVER PTX | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error